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Abstract: Inorganic arsenic is a known environmental toxicant and carcinogen of global public health concern. Arsenic is genotoxic 
and cytotoxic to human keratinocytes. However, the biological pathways perturbed in keratinocytes by low chronic dose inorganic 
arsenic are not completely understood. The objective of the investigation was to discover the mechanism of arsenic carcinogenicity in 
human epidermal keratinocytes. We hypothesize that a combined strategy of DNA microarray, qRT-PCR and gene function annotation 
will   identify aberrantly expressed genes in HaCaT keratinocyte cell line after chronic treatment with arsenic trioxide. Microarray data 
analysis identified 14 up-regulated genes and 21 down-regulated genes in response to arsenic trioxide. The expression of 4 up-  regulated 
genes and 1 down-regulated gene were confirmed by qRT-PCR. The up-regulated genes were AKR1C3 (Aldo-Keto Reductase fam-
ily 1, member C3), IGFL1 (Insulin Growth Factor-Like family member 1), IL1R2 (Interleukin 1 Receptor, type 2), and TNFSF18 
(Tumor Necrosis Factor [ligand] SuperFamily, member 18) and down-regulated gene was RGS2 (Regulator of G-protein Signaling 2). 
The observed over expression of TNFSF18 (167 fold) coupled with moderate expression of IGFL1 (3.1 fold), IL1R2 (5.9 fold) and 
AKR1C3 (9.2 fold) with a decreased RGS2 (2.0 fold) suggests that chronic arsenic exposure could produce sustained levels of TNF with 
  modulation by an IL-1 analogue resulting in chronic immunologic insult. A concomitant decrease in growth inhibiting gene (RGS2) and 
increase in AKR1C3 may contribute to chronic inflammation leading to metaplasia, which may eventually lead to carcinogenicity in the 
skin keratinocytes. Also, increased expression of IGFL1 may trigger cancer development and progression in HaCaT keratinocytes.
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Introduction
Inorganic arsenic is a known environmental toxicant 
and  carcinogen1,2  which  when  exposed  to  humans 
through inhalation or ingestion may result in human 
diseases such as intraepidermal carcinomas (Bowen 
disease),  squamous  cell  carcinomas  (SCC),  basal 
cell carcinomas (BCC), and Merkel cell carcinoma 
(MCC),  hyperkeratosis  and  hyperpigmentation.3 
Increasing reports of arsenic (As) related cancers in 
different  parts  of  the  world  including  southeastern 
Michigan (USA),4 India,5 Taiwan,6 and Bangladesh,7 
have raised more public health concerns about long-
term exposure to arsenic through drinking water or 
medications.
Inorganic  arsenic  is  genotoxic  and  cytotoxic  to 
keratinocytes.8  It  also  causes  alterations  of  gene 
expression in cultured human   keratinocytes.9 Though 
the molecular mechanisms of action are not completely 
understood,  it  is  known  that  arsenic  can  reduce 
DNA  repair,  increase  growth  factors,  induce  gene 
amplification,  reactive  oxygen  production  and 
oxidative  stress,  enhance  cell  proliferation,  and 
alter  DNA  methylation  and  signal  transduction.10 
Arsenic has low mutagenic activity and can serve as 
a   co-carcinogen.11 The intriguing property of arsenic 
trioxide is its ability to elicit apoptosis in some cell 
lines and tumorigenic in other cell lines. To explain 
the  molecular  mechanism  of  action  of  arsenic, 
high-throughput  gene  expression  studies  such  as 
microarray technologies were employed to investigate 
multiple mechanisms together based on alterations in 
expression of target genes.
DNA microarrays typically consist of thousands of 
immobilized DNA sequences present on a miniaturized 
surface.12 Microarrays have been used to propose a 
mechanism  of  arsenic  toxicity/carcinogenicity  in 
skin,13 kidney,14 myeloma,15 peripheral lymphocytes,13 
neural  tube,16  liver17  and  urogenital  cells.18  Other 
researchers have used microarrays to investigate the 
effects of arsenic on keratinocytes.19,20 There is still 
a  limited  number  of  public  domain  genome-wide 
gene expression datasets on the effect of arsenic on 
epidermal  cells  after  chronic  exposure. As  human 
exposure to arsenic occurs primarily through inges-
tion and skin contact, we selected HaCaT keratinocyte 
cell line for this in vitro study. HaCaT is the first 
permanent  immortalized  epithelial  cell  line  from 
adult human skin that exhibits normal differentiation 
and provides a promising tool for studying regulation 
of keratinization in human cells.21
The objective of the investigation was to discover 
the mechanism of arsenic carcinogenicity in human 
epidermal keratinocytes. We hypothesize that a com-
bined strategy of DNA microarray, RT-qPCR and gene 
function annotation will identify aberrantly expressed 
genes in HaCaT keratinocyte cell line after chronic 
treatment  with  arsenic  trioxide.  Knowledge  of  the 
biological pathways and networks of the genes that 
are  significantly  expressed  or  altered  are  pertinent 
to understanding the mechanism of action of arsenic 
carcinogenicity to HaCaT cells. Therefore, functional 
and pathway annotation using bioinformatics tools 
can help identify specific pathways of interest from 
the gene expression datasets.
In  this  article,  we  report  the  genes  aberrantly 
expressed  in  HaCaT  cells  in  response  of  chronic 
exposure to arsenic trioxide. The global transcriptomics 
approach  identified  over  expression  of  TNFSF18 
(tumor necrosis factor (ligand) superfamily, member 
18),  moderate  expression  of  IL1R2  (Interleukin  1 
receptor, type 2), IGFL1 (Insulin Growth Factor-Like 
family member 1) and  AKR1C3 (Aldo-Keto Reductase 
family  1,  member  C  3)  coupled  with  a  decreased 
expression  of  RGS2  (Regulator  of  G-protein 
  Signaling  2).  This  suggests  that  arsenic  exposure 
induces  immunotoxic,  anti-differentiation,  growth 
factor promotion and anti-apoptotic effects in skin 
keratinocytes.
Materials and Methods
Chemical and reagents
Arsenic  trioxide  (99.9%  purity,  Fisher    Scientific 
Suwanee, GA) and fetal bovine serum (FBS, Hyclone 
Laboratories  Logan,  UT)  were  purchased  for 
  culturing HaCaT cell line. Cell culture supplies such 
as   Dulbecco’s Minimum Essential Medium (DMEM), 
antibiotics,  and  phosphate  buffered  solution  (PBS) 
were purchased from ATCC.
Cell culture
Our experimental design included a control (untreated 
HaCaT cell), and test (Treated HaCaT cell) group. The 
HaCaT cell line was kindly provided by Dr. N. Fusenig 
(German  Cancer  Research  Center,  Heidelberg, Arsenic-induced aberrantly expressed genes in keratinocytes
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  Germany). 1.5 × 105 HaCaT cells were cultured in 
7.5  ml  of  complete  DMEM  containing  10%  Fetal 
Bovine Serum (FBS) and 1%   penicillin, streptomycin 
in T-25 culture plate. Cells were incubated in a humid-
ified atmosphere with 5% CO2 at 37 °C. The treatment 
groups were exposed to 5 mg/L As2O3 (equivalent to 
Lethal Concentration, LC 0.5%), and passaged at 90% 
  confluent. Chronic exposure was established by sub-
culturing the treatment group up to passage 22.
RnA extraction and gene expression
Total RNA was extracted from 4 technical replicates of 
unexposed HaCaT cells and HaCaT cells   chronically 
exposed to arsenic trioxide up to passage 22 using 
RNA STAT-60 (TEL-TEST, INC, Friendswood, TX, 
USA).22  A  NanoDrop  ND-1000  spectrophotometer 
(NanoDrop products, Wilmington, DE) was used to 
quantify the RNA by optical density reading. Also, 
the Agilent 2100 Bioanalyzer (Agilent Technologies, 
Palo Alto, CA) was used to determine the purity and 
quality of the extracted RNA. Only high quality RNA, 
having RNA Integrity Number (RIN) of .7.0,23 and 
an A260/280 absorbance ratio of .1.8, was utilized 
for microarray experiments.
Microarray
The  Human  Whole  Genome  OneArray™    (Phalanx 
Biotech, Palo Alto, CA) was used to perform DNA 
microarray  analysis.  RNA  was  converted  to 
  double-stranded cDNA and amplified using in vitro 
transcription systems that included amino-allyl UTP, 
and  the  aRNA  product  was  subsequently  con-
jugated  with  Cy5™  NHS  ester  (GEH  Lifesciences, 
  Pittsburgh, PA).   Fragmented aRNA was hybridized at 
42 °­ C   overnight using the HybBag mixing   system with 
1X   OneArray Hybridization Buffer (Phalanx   Biotech, 
Palo Alto,  CA),  0.01  mg/ml  sheared  salmon  sperm 
DNA (Promega, Madison, WI, USA), at a concentration 
of 0.025 mg/ml labeled target. After hybridization, the 
arrays  were  washed  according  to  the  OneArray 
  protocol. Raw intensity signals for each microarray 
were captured using a Molecular   Dynamics™ Axon 
4100A  scanner,  measured  using  GenePixPro™ 
  Software, and stored in GenePix Results (GPR)   format. 
The data from all microarrays in each experimental set 
was then passed to Rosetta Resolver (Rosetta Biosoft-
ware, Seattle, WA) for analysis.
Two-step quantitative RT-pCR
Relative quantitation using the comparative CT met-
hod24 was employed to confirm the microarray gene 
expression data. Untreated HaCaT cell sample was 
used as calibrator and Beta glucuronidase (GUSB) 
as  endogenous  control  gene  for  normalization.   
Applied Biosystems (Applied Biosystems,   Carlsbad, 
CA)  standard  protocol  was    followed.  The  RNA 
  samples were reverse-transcribed for 120 min at 37 °C 
with  High  Capacity  cDNA  Reverse  Transcription 
Kit. Quantitative PCR was carried out for 10 min at 
95 °C, and 40 cycles of 15 sec at 95 °C, 1 min at 
60 °C using 2X Power SYBR Green PCR Master Mix 
(Applied Biosystems, Carlsbad, CA) and 200 nM of 
forward and reverse primers. The primers are listed 
in Table 1. Triplicates of each assay were run on an 
Applied    Biosystems  7300  Real-Time  PCR  system 
and expression fold-changes were derived using the 
Table 1. Quantitative pCR primers for microarray validation.
Gene Forward Reverse
AKR1C3 GGAGAAGTGTAAGGATGCAGGATT GTACTTGAGTCCTGGCTTGTTGAG
GUSB TGATCGCTCACACCAAATCC CCCCTTGTCTGCTGCATAGTTA
IGFL1 CATCGTAGCTGTCTTTGCCATT TGGCTGGCACAGCATCAG
IL1R2 CACTACGCACCACAGTCAAGGA ATCCATATTCCCCCCAAAACC
MKnK1 CAACTCCTGTACCCCCATAACC TGGCCTGGTCCGTGAAGA
pCSK1 CCTGGAAGCAAACCCAAATC ATCCAAATCGACTATTCACCATCA
ppp1R13B GCCACACCACCTAAGAATTACCA GAGAGGTTGAACCCGAAGGTAAA
RGS2 GAATTCTGGCTGGCCTGTGA ATGTTTATCTCTTTTGGAGCTTCCTT
TM4SF4 TGGGCCTGAAGAACAATGACT CAAGAATCCAACCACAGCAAATAT
TMEM70 AAGGCATGGGATCGTTTCC ACTCCTGGCTCAATACTGATGGA
TnFSF18 AGCCCTGTATGGCTAAGTTTGG GCCATTCTGAAGTATCTCCAGCTTUdensi et al
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comparative threshold (CT) method. Each replicate 
cycle threshold (CT) was normalized to the average CT 
of GUSB on a per sample basis. Applied Biosystems 
formula was used to calculate the relative amount of 
the transcripts in the arsenic treated HaCaT and the 
untreated sample (control), and both were normal-
ized to the endogenous control (GUSB): ∆∆CT = ∆CT 
(treated) - ∆CT (control), where ∆CT is the difference 
in CT between the target gene and endogenous con-
trols by subtracting the average CT of controls. The 
fold-change for each treated sample relative to the 
control sample equals 2-∆∆CT.
Results
differentially expressed genes
The criterion for selection of differentially expressed 
genes  (DEGs)  was  a  fold  change  greater  than  or 
equal to 2. Comparison of the microarray data from 
untreated (control) and chronically exposed HaCaT 
keratinocyte cell identified a total of 35   differentially 
expressed genes with 14 genes up-regulated (Table 2) 
and  21  genes  down-regulated  (Table  3).  Genes 
with  $2  fold  changes  and  P-value  #0.05  were 
  considered   significantly expressed and were selected 
for  confirmation  using  qRT-PCR.  The    functional 
annotations  including  Gene  Ontology  for  these 
genes were   determined using the Michigan Molecu-
lar Interactions (MiMI) web tool25 (http://mimi.ncibi.
org).
Quantitative PCR confirmation  
of microarray data
Relative quantitation using the comparative CT method 
was employed to confirm the microarray gene   expression 
data. The expression of 4 up-regulated genes and 1 
down-regulated gene were confirmed by qRT-PCR for 
genes with a fold change of $2 when compared to the 
reference untreated control sample. The up-regulated 
genes were AKR1C3 (9.2 fold), IGFL1 (3.1), IL1R2 
(5.9 fold), and TNFSF18 (167 fold) and down-regulated 
Table 2. Genes up-regulated in response to chronic-dose 
exposure of arsenic trioxide to HaCaT keratinocyte cells.
Gene symbol Gene description
AGpAT4 1-acylglycerol-3-phosphate 
o-acyltransferase 4 (lysophosphatidic 
acid acyltransferase, delta) [
AKR1C2 aldo-keto reductase family 1, member 
C2 (dihydrodiol dehydrogenase 2;  
bile acid binding protein; 3-alpha 
hydroxysteroid dehydrogenase, type III)
AKR1C3 aldo-keto reductase family 1, 
member C3 (3-alpha hydroxysteroid 
dehydrogenase, type II)
C22orf42 Uncharacterized protein C22orf42
GLT6d1 glycosyltransferase 6 domain containing 1
IGFL1 IGF-like family member 1
IL1R2 interleukin 1 receptor, type II
KLHdC8A Kelch domain-containing protein 8A
nQo2 nAd(p)H dehydrogenase, quinone 2
pCSK1 proprotein convertase subtilisin/kexin 
type 1
STRAp STRAp serine/threonine kinase 
receptor associated protein
TMEM70 Transmembrane protein 70
TnFSF18 tumor necrosis factor (ligand) 
superfamily, member 18
ZFp36L1 zinc finger protein 36, C3H type-like
Table 3. Genes down-regulated in response to chronic-dose 
exposure of arsenic trioxide to HaCaT keratinocyte cells.
Gene symbol Gene description
CCdC150 coiled-coil domain containing 150
CLCC1 Chloride channel CLIC-like 1
CSRp1 Cysteine and glycine-rich protein 1
FGF1 Fibroblast growth factor 1 (acidic)
GCnT3 Glucosaminyl (n-acetyl) 
transferase 3, mucin type
GdA Guanine deaminase
HoXA5 homeobox A5
IMp5 Signal peptide peptidase-like 2C 
precursor (protein Spp-like 2C)
(protein SppL2c)(EC 3.4.23.-) 
(Intramembrane protease 5)(IMp5)
MAK male germ cell-associated kinase 
MKnK1 MAp kinase interacting serine/
threonine kinase 1
MRC2 mannose receptor, C type 2
np153 nucleoporin 153 kda
nT5C 5′, 3′-nucleotidase, cytosolic
pHF12 PHD finger protein 12
ppp1R13B Apoptosis-stimulating of p53 
protein, protein phosphatase 1, 
regulatory (inhibitor) subunit 13B
pRKAR1B protein kinase, cAMp-dependent, 
regulatory, type I, beta
RASL10A RAS-like, family 10, member A
RGS2 regulator of G-protein signaling 2, 
24kda
TM4SF4 transmembrane 4 L six family 
member 4
ToM1 target of myb1 (chicken)
ZnF19 zinc finger protein 19Arsenic-induced aberrantly expressed genes in keratinocytes
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gene was RGS2 (2.0 fold). A visualization comparing 
the fold change obtained by microarray and qRT-PCR 
for 9 genes is presented in Figure 1.
Biological pathway modeling
Ingenuity  Pathways  Analysis  (IPA;  Ingenuity 
  Systems, Redwood City, CA) was used to   determine 
models  of  biological  pathways  and  networks  that 
are    significantly  represented  in  the  differentially 
expressed (both up and down regulated) genes.
IPA identifies networks and pathways represented 
in the gene lists of interest. It generates a P-value for 
each network and canonical pathway, which is the like-
lihood that a given network was identified by chance. 
We selected networks scoring $2, which have .99% 
confidence of not being generated by chance.26
IPA assigns biological functions to each network by 
using annotations from scientific literature and stored 
in their knowledge base. Fisher exact test is used to 
calculate  the  P-value  for  each  biological  function/ 
disease or pathway being assigned by chance. We used 
Benjamini-Hochberg  corrected  P  #  0.05  to  select 
highly significant biological functions and pathways 
represented in the datasets analyzed.26
The predicted gene interaction pathways for the 
following  up-regulated  genes:  IL1R2,  TNFSF18 
and AKR1C3  are  presented  in  Figure  2,  Figure  3 
and    Figure  4  respectively.  Molecules  in  red  are 
up- regulated  while  molecules  in  green  are  down-
  regulated in the microarray data.
Discussion
In this investigation, the HaCaT keratinocyte cell line 
was used to pilot future investigations that will compare 
arsenic trioxide induced aberrantly expressed genes 
in a variety of human epidermal cells. The microarray 
experiment identified 14 up-regulated and 21 down-
regulated genes with expression fold change of $2 in 
HaCaT keratinocytes exposed to chronic dose of arsenic 
trioxide.  The  criterion  for  selecting  differentially 
expressed  genes  for  qRT-PCR  confirmation  was  a 
P-value #0.05 and fold change of $2. The following 
four up-regulated genes, AKR1C3 (9.2 fold), IGFL1 
(3.1  fold),  IL1R2  (5.9  fold),  and  TNFSF18  (167 
fold) and one down-regulated gene RGS2 (2.0 fold) 
were  selected  for  validation  using  complementary 
qRT-PCR  approach.  Subsequently,  annotations  for 
molecular function, cellular location and biological 
Gene QPCR
(Fold change) 
Microarray 
(Fold change)
AKR1C3
Aldo-keto reductase family 1, member C3 9.2 10.4
IGFL1
Insulin growth factor-like family member 13 .1 4.0
IL1R2
Interleukin 1 receptor, type II   5.94 .9
PCSK1
Proprotein convertase subtilisin/kexin type 1− 3.16 .9
PPP1R13B  
Protein phosphatase 1, regulatory (inhibitor) subunit 13B− 1.4− 100.0
RGS2
Regulator of G-protein signaling 2− 2.0− 9.9
TMEM70
Transmembrane protein 70 0.94 .0
TNFSF18
Tumor necrosis factor (ligand) superfamily, member 18   166.65 .9
GUSB
Beta glucuronidase  −1.2 −1.3
Figure 1. Comparison of fold change between microarray data and q-pCR data. Red: up-regulated; yellow: unchanged; green: down-regulated.Udensi et al
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pathway were determined using bioinformatics tools. 
The fold change values quantified by microarray and 
PCR do not agree well (Fig. 1). About half of the 
data pairs are significantly different and sometimes 
totally opposite. The big variances may be due to dif-
ferential transcript recognition by the two methods.27 
Furthermore,  different  hybridization  kinetics  may 
account for genes with identical microarray values 
but  with  dissimilar  qRT-PCR  values  (eg,  IGFL1 
and TMEM70). In most of the data pairs where the 
direction of expression is identical, the fold change 
was  higher  in  the  qRT-PCR  as  observed  by  other 
investigators.27
IL1R2  also  referred  to  as  CD121b,  IL1RB, 
and  MGC4772528  plays  a  vital  role  in  immune 
response  and  it  is  associated  with  the  membrane 
(Fig. 2). IL1R2 is a decoy receptor for inflammatory 
interleukin 1 (IL-1). It acts by sequestering active and 
inactive IL1, which in turn restricts the availability 
of the ligand for the functional receptor and inhibits 
its maturation.29–32 IL1R1 and IL1R2 are the known 
receptors of IL1 and cell activation which is capable 
of  transducing  the  activation  signal  which  occurs 
when IL1 binds to cell surface IL1R1 in conjunction 
with  IL1R  accessory  protein  (IL1RAP).33  IL1R2 
is known as a potent,   specific and natural inhibitor 
of IL1, but in contrast to IL1R1 it has no signaling 
properties when bound to IL1.29–32 Over expression 
of IL1R2 has been reported in human uroepithelial 
cell line (HUC-1)   chronically exposed to arsenite.34 
Our results confirmed this   observation in HaCaT cell 
line. ILIR2 may therefore be a biomarker for chronic 
exposure to arsenicals. In our investigation, HaCaT 
cells were chronically exposed to low arsenic trioxide 
dose of 5 mg/L up to 22 passages. In HUC-1, IL1R2 
over expression is linked with enhanced expression 
of Smad-interacting protein 1 (SIP-1) and reduced 
expression of E-cadherin.34
E-cadherin is a calcium-dependent, epithelial cell 
adhesion molecule, whose reduced expression has been 
associated with tumor dedifferentiation and increased 
lymph node metastasis in clinical studies involving 
several carcinomas.35 Furthermore, reduced expression 
levels of E-cadherin was associated with moderately 
IL1A
IL1RAP
IL1R2
GLI1
IL1B
Figure 2. Interaction network of Interleukin 1 Receptor, Type II (IL1R2). 
Molecules in red are up-regulated while molecules in green are down-
regulated in the microarray analysis data.
IL2
Lipopolysaccharide
NFkB (complex)
Tnf
TNFSF18
TNFRSF18
Nuclear factor 1
Figure 3. Interaction network for TnFSF18 interaction network. Molecules in red are up-regulated while molecules in green are down-regulated in the 
microarray data.Arsenic-induced aberrantly expressed genes in keratinocytes
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and  poorly  differentiated  squamous  and  small  cell 
carcinoma in a limited number of patients with lung 
cancer.36 IL1R2 also improves cell migration34 and 
are suggestive of   oncogenic potential of IL1R2. Gene 
network analysis with IL1R2 gene as illustrated in 
Figure 2, showed that IL1R2   interacts with IL1RAP, 
IL1A, IL1B and GLI1 and this agrees with previous 
findings.29–32  GLI1,  a  protein  which  was  originally 
isolated from human glioblastoma37,38 is the effector 
of  Hedgehog  (Hh)  signaling  which  critical  role  in 
  carcinogenesis.39 Furthermore, GLI1 was reported to 
be upregulated in many tumors including basal cell 
carcinomas. Arsenic ingestion through drinking water 
has also been linked with increased risk of basal cell 
carcinomas (BCC).40 Thus, ILIR2 indirectly interacts 
with GLI1, which is the trigger for BCC indicative of 
contribution in skin carcinogenesis.
The  cytokine  TNFSF18,  which  can  also  be 
represented as glucocorticoid-induced tumor necrosis 
factor receptor-related ligand (GITRL), is a ligand for 
receptor  TNFRSF18/AITR/GITR  and  it  modulates 
T lymphocyte survival in peripheral tissues41 (Fig. 3). 
TNFSF18 is found in extracellular space and integral 
to  membrane.42  We  observed  that  TNFSF18  was 
  significantly over expressed with fold change of more 
than 167. The glucocorticoid-induced tumour necro-
sis factor receptor-related gene (GITR) is expressed 
on regulatory T-cells (Treg), which are CD4+CD25+ 
lymphocytes. Binding of the GITR-ligand (GITRL) 
leads to down-regulation of the biology function of 
Tregs. It is believed that a defect in Tregs causes a 
skin condition resembling atopic dermatitis.43   Soluble 
forms of GITRL (sGITRL) are released by human 
tumor  cells.44  This  suggests  that  determination  of 
sGITRL  levels  might  be  implemented  as  a  tumor 
marker in patients.
Activated  keratinocytes  are  known  to  engage 
intraepithelial  T-cells  through  co-stimulatory  mol-
ecules,  keratinocytes  express  GITRL  and  through 
this important co-stimulatory molecule expressed by 
antigen-presenting cells (APCs).45 Furthermore, they 
have the potential to influence T-cell numbers in the 
skin via chemokine production and through a direct 
cell-cell effect on T-cell proliferation. This means that 
C1ORF103 Prostaglandin-F synthase
T3-TR-RXR
Propylthiouracil
Methylprednisolone
UBE2W
HNF4A
Androsterone
Indan-1-ol
Bexarotene
Naringenin
RIF1
ACIN1
Luteolin
Prostaglandin h2
20alpha-hydroxysteroid dehydrogenase
3alpha-hydroxysteroid dehydrogenase (A-specific)
MAGEA11
Androgen
Silibinin
Testosterone
Quercetin
Alefacept
PTEN
Prostaglandin F2alpha
Apigenin
HNF1A
Progesterone
ZHX1
AG490
(+/−)-trans-7, 8-dihydroxy-7, 8-dihydro-5-methylchrysene
(+/−)-trans-7, 8-dihydroxy-7, 8-dihydrobenzo[a]pyrene
(+/−)-trans-3, 4-dihydroxy-3, 4-dihydro-benzo[c]phenanthrene
(+/−)-trans-3, 4-dihydroxy-3, 4-dihydrobenz[a]anthracene
(+/−)-trans-3, 4-dihydroxy-3, 4-dihydro-7-mehtylbenz[a]anthracene
(+/−)-trans-1, 2-dihydroxy-1, 2-dihydrochrysene
(+/−)-trans-1, 2-dihydroxy-1, 2-dihydronaphthalene
(+/−)-trans-3, 4-dihydroxy-3, 4-dihydro-7, 12-dimethylbenz[a]anthracene
Trans-1, 2-dihydrobenzene-1, 2-diol dehydrogenase
Trans-7, 8-dihydroxy-7, 8-dihydrobenzo(a)pyrene
Trans-(±)-3, 5-cyclohexadiene-1, 2-diol
(+/−)-trans-11, 12-dihydroxy-11, 12-dihydro-benzo[g]chrysene
Figure 4. Interaction network for AKR1C3. Molecules in red are up-regulated while molecules in green are down-regulated in the microarray data.Udensi et al
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sustained arsenic insult could have activated the HaCaT 
  keratinocytes, which may lead to an immunotoxigenic 
reaction as reported by   Baumgartner-Nielsen et al.43
Aldo-keto reductase family 1, member C3 (3-alpha 
hydroxysteroid dehydrogenase, type II) (AKR1C3) 46 
was up-regulated up to 9.2 folds in our investigation. 
Human AKR1C3  is  an  enzyme  involved  in    steroid 
metabolism as illustrated in Figure 4. Elevated   levels 
of AKR1C3  expression  are  implicated  in    leukemia 
cell differentiation, prostate cancer (in both androgen-
  dependent and androgen-independent prostate cancer),47 
endometrial cancer48 and chronic inflammation.47
We observed a moderate expression (3.1 fold) of 
insulin growth factor-like family member 1 (IGFL1). 
The IGF-like (IGFL1) genes encode proteins that con-
tain 11 conserved cysteine residues at fixed positions 
including two CC motif.49 The biological functions and 
gene interactions of IGFL1 is not very clear, however, 
the structure and sequence suggest that IGFL proteins 
are distantly related to the Insulin-like growth factors 
(IGF),  a  superfamily  of  growth  factors.  Both  IGFL 
and IGF share gene expression patterns in many can-
cers.49 The human skin is the critical organ of arsenic 
toxicity because arsenic has a strong affinity for the 
keratin proteins, which are rich in the sulphur contain-
ing cysteine residues50 and potentially arsenic-binding 
proteins based on presence of vicinal cysteines.51 In 
our previous investigation,52 we observed that proteins 
with  abundance  of  vicinal  cysteines  will  increase 
responsiveness  to  arsenic-induced  keratinocyte 
carcinogenesis.  Since  IGLF1  encodes  proteins  rich 
in cysteine residues, it could be playing a vital role in 
arsenic binding and responsiveness in keratinocytes. 
Further, IGFL1 is associated with embryonic tissue and 
was observed in libraries derived from carcinoma cell 
lines.49 Therefore, the increase in IGFL1 is involved 
in cancer development and progression and probably a 
marker of chronic exposure to arsenic trioxide.
The  growth  suppressor  gene  RGS2    accelerate 
GTPase activity of heterotrimeric G proteins, resulting 
in  inactivation  of  specific  signaling    pathways.53 
Down regulation of RGS2 occurred in human pros-
tate tumor specimens54 as well as in recurrence and 
  metastasis-derived  colorectal  cancer  cell  lines.55 
In HaCaT keratinocyte cells, aberrant expression of 
RGS2 may aid in the spread of cancer or metastasis.
In  conclusion,  we  have  used  a  combination  of 
microarray, gene functional annotation data and qPCR 
to identify genes differentially expressed in HaCaT 
cell  line  in  response  to  chronic,  low  dose  arsenic 
trioxide.  Two  immune  response  genes  IL1R2  and 
TNFSF18 were identified which may result to chronic 
immunologic insult in keratinocytes. Also, the down 
regulation  of  growth  inhibiting  gene  (RGS2)  and 
upregulation of AKR1C3 and IGLF1 may aid chronic 
inflammation leading to metaplasia.
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